使用糖蛋白IIb/IIIa拮抗剂进行治疗可抑制患者富血小板血浆中的凝血酶生成。
Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
作者信息
Keularts I M, Béguin S, de Zwaan C, Hemker H C
机构信息
Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, The Netherlands.
出版信息
Thromb Haemost. 1998 Sep;80(3):370-1.
Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity, inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.
输注糖蛋白IIb/IIIa抑制剂MK383可通过干扰血小板促凝磷脂暴露的产生来抑制富含血小板血浆中的凝血酶生成。其效果与0.2 U/ml肝素的效果相似。众所周知，肝素通过促进抗凝血酶活性来抑制凝血酶生成，它可能通过减少游离凝血酶的形成来抑制血小板衍生促凝微粒的形成，在我们的实验条件下，游离凝血酶是主要的血小板激活剂。
Zotero 插件